Position in CELC
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$7,474,575
+$504,274 QoQ
Shares Held
71,445
+17.0% QoQ
Ownership
0.146%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#76
of 274 holders
Holding Since
Jun 2020
25 quarters on record
Voting authority
Sole 14%
Shared 0%
None 86%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CAPTRUST FINANCIAL ADVISORS holds $167,363,866 across 124 Biotechnology names. CELC ranks #7 (4.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
36,464 | $22,736,762 | |
| 2 | RPRX |
Royalty Pharma plc
|
337,298 | $18,912,298 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
35,471 | $17,619,509 | |
| 4 | EXEL |
Exelixis, Inc.
|
303,042 | $16,488,515 | |
| 5 | LGND |
Ligand Pharmaceuticals Inc
|
34,607 | $10,938,926 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
125,946 | $9,857,793 | |
| 7 | CELC |
Celcuity Inc.
This page
|
71,445 | $7,474,575 | |
| 8 | INCY |
Incyte Corp
|
50,301 | $5,702,121 |
All Filings in CELC
Export CSV
25 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,474,575 | 71,445 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $6,970,301 | 61,068 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $6,137,002 | 61,530 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $3,336,229 | 67,535 | Shares | Sole | 2025-11-19 | |
| 2025-06-30 | $7,615,387 | 570,441 | Shares | Sole | 2025-08-15 | |
| 2025-03-31 | $5,637,366 | 557,603 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $6,127,376 | 468,096 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $6,885,348 | 461,794 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $7,564,775 | 461,830 | Shares | Sole | 2024-08-15 | |
| 2024-03-31 | $10,092,492 | 467,245 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $7,938,245 | 544,835 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $5,053,487 | 552,898 | Shares | Sole | 2023-11-15 | |
| 2023-06-30 | $6,131,945 | 558,465 | Shares | Sole | 2023-08-15 | |
| 2023-03-31 | $5,843,986 | 570,145 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $8,839,063 | 630,911 | Shares | Sole | 2023-02-15 | |
| 2022-09-30 | $6,357,217 | 633,189 | Shares | Sole | 2022-11-16 | |
| 2022-06-30 | $45,500 | 5,000 | Shares | Sole | 2022-08-23 | |
| 2022-03-31 | $46,750 | 5,000 | Shares | Sole | 2022-05-16 | |
| 2021-12-31 | $65,950 | 5,000 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $90,000 | 5,000 | Shares | Sole | 2021-11-16 | |
| 2021-06-30 | $120,000 | 5,000 | Shares | Sole | 2021-08-16 | |
| 2021-03-31 | $71,700 | 5,000 | Shares | Sole | 2021-05-17 | |
| 2020-12-31 | $45,800 | 5,000 | Shares | Sole | 2021-02-16 | |
| 2020-09-30 | $29,000 | 5,000 | Shares | Sole | 2020-11-17 | |
| 2020-06-30 | $34,650 | 5,000 | Shares | Sole | 2020-08-14 | |
| No filing history on record for this holder in this stock. | ||||||